UNICANCER

Their core work

UNICANCER is the French federation of comprehensive cancer centres, coordinating clinical research, patient care pathways, and translational oncology across its member hospitals. Their H2020 work focuses on running large international clinical studies — particularly around personalised cancer screening and biomarker-driven diagnostics. They bring the clinical trial infrastructure, patient cohorts, and oncology expertise that most research consortia lack, acting as the operational backbone for multi-country cancer studies.

What they specialise in

How they've shifted over time

Their first H2020 engagement (MyPeBS, 2018) focused narrowly on breast cancer and screening methodology — genetics, polymorphisms, mammography, and risk scoring. By 2019 with ONCOBIOME, their work broadened substantially into multi-cancer diagnostics (colon, melanoma, lung) and moved from screening into molecular-level biomarker discovery using microbiome signatures. The trajectory is clear: from a single-disease, population-screening approach toward multi-cancer precision diagnostics and immunotherapy response prediction.

UNICANCER is moving from population-scale screening trials toward molecular biomarker and microbiome-driven precision oncology — a good fit for partners working on diagnostic assays, immunotherapy, or AI-based patient stratification.

How they like to work

UNICANCER takes the lead when the work matches its core strength (coordinating MyPeBS, a EUR 3.1M international trial) and joins as a participant when the science sits outside its operational specialty. With 51 partners across 12 countries from only two projects, they plug into large, diverse consortia rather than tight repeat-partner circles. Expect them to contribute clinical infrastructure and patient access rather than bench-level molecular work.

51 consortium partners across 12 countries from just two projects, indicating participation in large, pan-European clinical consortia. The geographic spread is clearly European with an international clinical-trial reach typical of oncology research.

What sets them apart

Unlike individual cancer centres or academic labs, UNICANCER aggregates France's entire comprehensive cancer centre network under one consortium partner — giving collaborators access to a federated patient cohort and harmonised clinical protocols in a single contract. For any consortium needing large-scale cancer patient recruitment, clinical data, or multi-site trial execution in France, they are effectively the single entry point. This makes them unusually valuable for studies requiring statistical power that no single hospital can provide.

Highlights from their portfolio

• MyPeBS
  Their flagship H2020 engagement — coordinator role on a EUR 3.1M international randomised trial testing whether personalised risk-based screening outperforms standard mammography.
• ONCOBIOME
  Signals their expansion beyond breast cancer into microbiome-based diagnostics across four cancer types, linking gut bacteria to immunotherapy response.